Get the Stockscreener App
10.04
0.10%
0.010
After Hours:
10.04
Translational Development Acquisition Corp Stock (TDAC) Latest News
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Major SPAC Update: TDACU Splits Units into Separate Shares & Warrants Trading - StockTitan
Trident Acquisitions stock hits 52-week high of $10.08 By Investing.com - Investing.com Australia
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
TDACU stock touches 52-week low at $10.01 amid market shifts - Investing.com UK
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Translational Development Acquisition Corp Launches $150M IPO on Nasdaq, Units to Trade as TDACU - StockTitan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel - GlobeNewswire
IPO NewsUS IPO Weekly Recap: Sizable tech and biotech IPOs are joined by a flurry of small names - Renaissance Capital
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer - PR Newswire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Merck to Acquire Caraway Therapeutics, Inc. - Business Wire
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
FirstEnergy issues earnings report - 69News WFMZ-TV
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Research and Development grant cheat sheet - University of Sydney
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
BioSpace Movers & Shakers, March 19 - BioSpace
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. - Business Wire
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy - Business Wire
Takeda Takes Stake, Inks Deal With Newly Launched Izana Bioscience - BioSpace
Quotient Clinical’s second U.S. acquisition in a row: Charles River’s QS Pharma - Fierce Biotech
What You Need to Know About Denali - BioSpace
Three Former Genentech Researchers Launch Neuroscience Company Denali Therapeutics With $217 Million - BioSpace
People - Nature.com
1.35%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):